O	0	8	Analysis
O	9	11	of
O	12	24	chemotherapy
O	24	25	-
O	25	32	induced
O	33	43	amenorrhea
O	44	49	rates
O	50	52	by
O	53	58	three
O	59	68	different
B-intervention	69	82	anthracycline
I-intervention	83	86	and
I-intervention	87	93	taxane
O	94	104	containing
O	105	113	regimens
O	114	117	for
O	118	123	early
O	124	130	breast
O	131	137	cancer
O	137	138	.

O	139	151	Chemotherapy
O	151	152	-
O	152	159	induced
O	160	170	amenorrhea
O	171	172	(
O	172	175	CIA
O	175	176	)
O	177	179	by
O	180	185	newer
O	186	192	taxane
O	192	193	-
O	193	203	containing
O	204	212	regimens
O	213	216	was
O	217	226	evaluated
O	227	229	in
O	230	235	early
O	236	242	breast
O	243	249	cancer
O	250	251	(
O	251	254	EBC
O	254	255	)
O	256	264	patients
O	264	265	.

O	266	267	A
O	268	279	prospective
O	280	286	cohort
O	287	289	of
B-total-participants	290	293	122
B-eligibility	294	307	premenopausal
I-eligibility	308	311	EBC
I-eligibility	312	320	patients
O	321	333	participated
O	334	336	in
O	337	338	a
O	339	344	phase
O	345	348	III
O	349	354	trial
O	355	357	of
O	358	370	preoperative
O	371	380	docetaxel
O	380	381	/
O	381	393	capecitabine
O	394	395	(
O	395	397	TX
O	397	398	)
O	399	405	versus
B-control	406	417	doxorubicin
I-control	417	418	/
I-control	418	434	cyclophosphamide
I-control	435	436	(
I-control	436	438	AC
I-control	438	439	)
O	439	440	;
B-intervention-participants	441	443	34
O	444	452	patients
O	453	461	received
O	462	470	adjuvant
O	471	473	AC
O	474	482	followed
O	483	485	by
O	486	496	paclitaxel
O	497	498	(
O	498	499	T
O	499	500	)
O	501	504	and
B-control-participants	505	508	129
O	509	517	patients
O	518	526	received
O	527	528	5
O	528	529	-
O	529	541	fluorouracil
O	541	542	/
O	542	553	doxorubicin
O	553	554	/
O	554	570	cyclophosphamide
O	571	572	(
O	572	575	FAC
O	575	576	)
O	576	577	.

O	578	581	The
B-outcome	582	585	CIA
I-outcome	586	590	rate
O	591	594	was
B-iv-bin-percent	595	597	90
I-iv-bin-percent	597	598	.
I-iv-bin-percent	598	599	2
I-iv-bin-percent	599	600	%
O	601	605	with
O	606	608	TX
O	608	609	/
O	609	611	AC
O	611	612	,
B-iv-bin-percent	613	615	73
I-iv-bin-percent	615	616	.
I-iv-bin-percent	616	617	5
I-iv-bin-percent	617	618	%
O	619	623	with
O	624	626	AC
O	627	635	followed
O	636	638	by
O	639	640	T
O	640	641	,
O	642	645	and
B-cv-bin-percent	646	648	72
I-cv-bin-percent	648	649	.
I-cv-bin-percent	649	650	1
I-cv-bin-percent	650	651	%
O	652	656	with
O	657	660	FAC
B-outcome	661	663	at
I-outcome	664	665	1
I-outcome	666	670	year
O	671	672	(
O	672	673	P
O	674	675	=
O	676	677	0
O	677	678	.
O	678	681	002
O	681	682	)
O	682	683	,
O	684	687	and
B-iv-bin-percent	688	690	66
I-iv-bin-percent	690	691	.
I-iv-bin-percent	691	692	7
I-iv-bin-percent	692	693	%
O	693	694	,
B-iv-bin-percent	695	697	73
I-iv-bin-percent	697	698	.
I-iv-bin-percent	698	699	3
I-iv-bin-percent	699	700	%
O	700	701	,
O	702	705	and
B-cv-bin-percent	706	708	58
I-cv-bin-percent	708	709	.
I-cv-bin-percent	709	710	9
I-cv-bin-percent	710	711	%
O	711	712	,
O	713	725	respectively
O	725	726	,
B-outcome	727	729	at
I-outcome	730	731	3
I-outcome	732	737	years
O	738	739	(
O	739	740	P
O	741	742	=
O	743	744	0
O	744	745	.
O	745	748	268
O	748	749	)
O	749	750	.

O	751	753	At
O	754	757	one
O	758	762	year
O	762	763	,
O	764	767	age
O	768	769	(
O	769	770	P
O	771	772	<
O	773	774	0
O	774	775	.
O	775	778	001
O	778	779	)
O	780	783	and
O	784	790	taxane
O	791	794	use
O	795	796	(
O	796	797	P
O	798	799	=
O	800	801	0
O	801	802	.
O	802	805	002
O	805	806	)
O	806	807	,
O	808	811	and
O	812	817	after
O	818	821	two
O	822	827	years
O	827	828	,
O	829	832	age
O	833	836	and
O	837	846	tamoxifen
O	847	850	use
O	851	855	were
O	856	867	significant
O	868	875	factors
O	876	879	for
O	880	883	CIA
O	884	886	in
O	887	899	multivariate
O	900	908	analysis
O	908	909	.

B-outcome	910	915	Serum
I-outcome	916	925	estradiol
I-outcome	926	929	and
I-outcome	930	938	follicle
I-outcome	938	939	-
I-outcome	939	950	stimulating
I-outcome	951	958	hormone
I-outcome	959	965	levels
O	966	970	were
O	971	984	significantly
O	985	995	correlated
O	996	1000	with
O	1001	1010	menstrual
O	1011	1017	status
O	1017	1018	,
O	1019	1022	age
O	1022	1023	,
O	1024	1027	and
O	1028	1037	tamoxifen
O	1038	1041	use
O	1041	1042	.

O	1043	1050	Taxanes
O	1051	1059	resulted
O	1060	1062	in
O	1063	1069	higher
O	1070	1073	CIA
O	1074	1079	rates
O	1080	1082	in
O	1083	1086	the
O	1087	1092	first
O	1093	1097	year
O	1097	1098	,
O	1099	1102	but
O	1103	1106	age
O	1107	1110	and
O	1111	1120	tamoxifen
O	1121	1124	use
O	1125	1129	were
O	1130	1141	significant
O	1142	1149	factors
O	1150	1153	for
O	1154	1164	persistent
O	1165	1168	CIA
O	1168	1169	.
